> top > docs > PMC:7784786 > spans > 16529-18065 > annotations

PMC:7784786 / 16529-18065 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
585 98-102 Gene denotes IL-6 Gene:3569
586 204-208 Gene denotes IL-6 Gene:3569
587 58-66 Species denotes patients Tax:9606
588 181-189 Species denotes Patients Tax:9606
589 68-78 Chemical denotes itolizumab MESH:C000597346
590 128-138 Chemical denotes itolizumab MESH:C000597346
591 43-57 Disease denotes critically ill MESH:D016638
592 441-450 Disease denotes mortality MESH:D003643
593 467-475 Disease denotes COVID-19 MESH:C000657245
596 636-655 Disease denotes coronavirus disease MESH:D018352
597 657-665 Disease denotes COVID-19 MESH:C000657245
601 820-823 Gene denotes CD6 Gene:923
602 814-819 Species denotes human Tax:9606
603 752-762 Chemical denotes Itolizumab MESH:C000597346
607 928-936 Disease denotes COVID-19 MESH:C000657245
608 964-984 Disease denotes respiratory distress MESH:D012128
609 999-1032 Disease denotes multifocal interstitial pneumonia
612 1038-1046 Species denotes patients Tax:9606
613 1065-1075 Chemical denotes itolizumab MESH:C000597346
618 1142-1146 Gene denotes IL-6 Gene:3569
619 1184-1192 Species denotes patients Tax:9606
620 1111-1121 Chemical denotes Itolizumab MESH:C000597346
621 1175-1183 Disease denotes COVID-19 MESH:C000657245
623 1198-1206 Species denotes patients Tax:9606
625 1287-1297 Chemical denotes Itolizumab MESH:C000597346
628 1501-1510 Disease denotes mortality MESH:D003643
629 1527-1535 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T55 568-593 Phenotype denotes cytokine-release syndrome http://purl.obolibrary.org/obo/HP_0033041
T56 964-984 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T57 1023-1032 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T145 0-10 Sentence denotes Conclusion
T146 11-118 Sentence denotes In summary, in these severe and critically ill patients, itolizumab was able to reduce IL-6 concentrations.
T147 119-180 Sentence denotes Notably, itolizumab-related adverse events were not reported.
T148 181-282 Sentence denotes Patients with baseline IL-6 levels below 200 pg/ml, showed prompt clinical and radiological recovery.
T149 283-476 Sentence denotes We anticipate that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19.
T150 477-539 Sentence denotes The analysis of the complete-series will be published shortly.
T151 540-554 Sentence denotes Summary points
T152 555-667 Sentence denotes Inflammatory cytokine-release syndrome is associated with the progression of the coronavirus disease (COVID-19).
T153 668-751 Sentence denotes No current therapy has proven effective for the management of this syndrome so far.
T154 752-910 Sentence denotes Itolizumab is a humanized monoclonal antibody that recognizes human CD6 and its effect is associated with the reduction of pro-inflammatory cytokines release.
T155 911-1033 Sentence denotes We present three COVID-19 cases who developed severe respiratory distress together with multifocal interstitial pneumonia.
T156 1034-1110 Sentence denotes The patients were treated with itolizumab combined with antiviral therapies.
T157 1111-1193 Sentence denotes Itolizumab reduced circulating IL-6 concentrations in the three COVID-19 patients.
T158 1194-1286 Sentence denotes Two patients showed rapid ventilatory and radiological improvement and were fully recovered.
T159 1287-1339 Sentence denotes Itolizumab-related adverse events were not reported.
T160 1340-1536 Sentence denotes These cases show that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19.